FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to a combined application of pharmaceuticals from the groups of cytostatics or proteasome inhibitors with a recombinant analogue of the protein SLURP-1 with SEQ ID NO:1 for inhibiting the growth of carcinomas, and can be used in medicine.
EFFECT: proposed method allows increasing effectiveness of pharmaceuticals from the groups of cytostatics and proteasome inhibitors and lowering concentrations thereof required to suppress tumour growth.
2 cl, 2 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PEPTIDE HAVING ACTIVITY OF HUMAN SLURP-1 PROTEIN AND ITS APPLICATION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA, AND METHOD FOR SUPPRESSION OF GROWTH OF CARCINOMA AND GLIOMA USING THE SPECIFIED PEPTIDE | 2022 |
|
RU2792364C1 |
| USE OF RECOMBINANT ANALOGUE OF WATER-SOLUBLE DOMAIN OF LYNX1 PROTEIN FOR CELL GROWTH INHIBITION BY CARCINOMA | 2019 |
|
RU2721129C1 |
| IMMUNOCYTOKINE FOR ACTIVATION OF HUMAN IL-10Rα RECEPTOR AND ITS USE | 2020 |
|
RU2810750C2 |
| METHODS FOR TREATING CANCER, INCLUDING TIGIT-BINDING AGENTS | 2017 |
|
RU2765410C2 |
| ANTIBODIES FOR TREATING CANCER, IN WHICH CLAUDIN 6 IS EXPRESSED | 2012 |
|
RU2816850C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| ANTIBODIES SPECIFIC TO CD47 AND PD-L1 | 2020 |
|
RU2779652C2 |
| HIGHLY EFFECTIVE METHOD FOR PREPARING DOSAGE FORM OF TARGETED ACTION FOR THERAPY OF MALIGNANT GROWTHS | 2019 |
|
RU2727924C1 |
| COMBINATION THERAPY USING ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER TREATMENT | 2014 |
|
RU2792932C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
